 Considering the significant activity of the combination of Bevacizumab irinotecan in patients with recurrent GBM, and considering the activity of temozolomide in GBM, it is proposed that the combination of Bevacizumab Temozolomide may also be an active regimen. Bevacizumab Temozolomide display non-overlapping toxicity clinically and thus their combined use without significant dose-reductions seems rational. 